Early hbeag loss during peginterferon α-2b therapy predicts HBsAg loss: Results of a long-term follow-up study in chronic hepatitis B patients

American Journal of Gastroenterology

Volumn 104, Issue 10, 2009, Pages 2449-2457

  Buster, Erik H C J ^a   Flink, Hajo J ^a   Simsek, Halis ^b   Heathcote, E Jenny ^c   Sharmila, Sachithanandan ^d   Kitis, George E ^e   Gerken, Guido ^f   Buti, Maria ^g   De Vries, Richard A ^h   Verhey, Elke ^a   Hansen, Bettina E ^a   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HACETTEPE UNIVERSITY   (Turkey)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d Selayang Hospital   (Malaysia)

^e General Hospital George Papanikolaou   (Greece)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2B; VIRUS DNA; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; AREA UNDER THE CURVE; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; LONGITUDINAL STUDY; NONPARAMETRIC TEST; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; POLYETHYLENE GLYCOLS; STATISTICS, NONPARAMETRIC;

EID: 70350475693     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.371     Document Type: Article

References (28)

1. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48:335-352
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107
3. Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004; 351:2832-2838
4. Papatheodoridis GV, Manolakopoulos S, Dusheiko G et al. The rapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8:167-178
5. Krogsgaard K. The long-term Effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat 1998; 5:389-397
6. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAgpositive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334:1422-1427
7. van Zonneveld M, Honkoop P, Hansen BE et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39:804-810
8. Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123-129
9. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695
10. Wong DK, Cheung AM, O'Rourke K et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119:312-323
11. Buster EH, Flink HJ, Cakaloglu Y et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135:459-467
12. Cooksley G, Lau GKK, Liaw YF et al. Effects of genotype and other baseline factors on response to peginterferon alfa-2a (40 kDa) (Pegasys) in HBeAgpositive chronic hepatitis B: results from a large, randomised study. J Hepatol 2005; 42:S30
13. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539
14. Pas SD, Fries E, De Man RA et al. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 2000; 38:2897-2901
15. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699
16. Hou J, Schilling R, Janssen HL et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol 2007; 79:1055-1063
17. Kobayashi M, Suzuki F, Akuta N et al. Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine. J Med Virol 2007; 79:1472-1477
18. Piratvisuth T, Lau GKK, Marcellin P et al. Association between HBeAg seroconversion and sustained HBV DNA suppression in patients treated with peginterferon alfa-2a (40KD) for HBeAg-positive chronic hepatitis B. J Hepatol 2006; 44:S23
19. Cooksley WG, Piratvisuth T, Lee SD et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10:298-305
20. Di Bisceglie A, Lai CL, Gane E et al. Telbivudine GLOBE trial: Maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 2006; 44:230A-1A
21. van der Eijk AA, Niesters HG, Hansen BE et al. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha. J Viral Hepat 2006; 13:96-103
22. Fried MW, Piratvisuth T, Lau GK et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47:428-434
23. Carreno V, Castillo I, Molina J et al. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol 1992; 15:102-106
24. Fattovich G, Giustina G, Realdi G et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26:1338-1342
25. Korenman J, Baker B, Waggoner J et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114:629-634
26. Lau DT, Everhart J, Kleiner DE et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113:1660-1667
27. Lin SM, Sheen IS, Chien RN et al. Long-term beneficial Effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29:971-975
28. Lok AS, Chung HT, Liu VW et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105:1833-8.